Publications by authors named "Matthew A Marx"

Claim this Profile
A
Absorption, single-dose and steady-state metabolism, excretion, and pharmacokinetics of adagrasib, a KRAS inhibitor.
Lisa Rahbaek, Cornelius Cilliers, Christopher J Wegerski, Natalie Nguyen, Jennifer Otten, Matthew A Marx

Cancer Chemother Pharmacol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading.
Niranjan Sudhakar, Larry Yan, Fadia Qiryaqos, Lars D Engstrom, Jade Laguer, Matthew A Marx

Mol Cancer Ther· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Z
Zirconium Hydride Catalysis Initiated by Tetrabutylammonium Fluoride.
Athenea N Aloiau, Briana M Bobek, Kelly E Pearson, Kendall E Cherry, Christopher R Smith, Matthew A Marx

J Org Chem· August 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stereoselective Amine Synthesis Mediated by a Zirconocene Hydride to Accelerate a Drug Discovery Program.
Athenea N Aloiau, Briana M Bobek, Kersti Caddell Haatveit, Kelly E Pearson, Ashlee H Watkins, Matthew A Marx

J Org Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Pyridopyrimidinones that Selectively Inhibit the H1047R PI3Kα Mutant Protein.
John M Ketcham, Stephen J Harwood, Ruth Aranda, Athenea N Aloiau, Briana M Bobek, Matthew A Marx

J Med Chem· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Five SOS2 Fragment Hits with Binding Modes Determined by SOS2 X-Ray Cocrystallography.
Christopher R Smith, Dan Chen, James G Christensen, René Coulombe, James Féthière, Matthew A Marx

J Med Chem· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
MRTX1719 Is an MTA-Cooperative PRMT5 Inhibitor That Exhibits Synthetic Lethality in Preclinical Models and Patients with MTAP-Deleted Cancer.
Lars D Engstrom, Ruth Aranda, Laura Waters, Krystal Moya, Vickie Bowcut, Matthew A Marx

Cancer Discov· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Optimization of mTOR Inhibitors Using Property-Based Drug Design and Free-Wilson Analysis for Improved In Vivo Efficacy.
Sean T Murphy, Joy Atienza, Jason W Brown, Zacharia S Cheruvallath, Matthew J Cukierski, Matthew A Marx

ACS Med Chem Lett· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment optimization and elaboration strategies - the discovery of two lead series of PRMT5/MTA inhibitors from five fragment hits.
Christopher R Smith, Svitlana Kulyk, Misbha Ud Din Ahmad, Valentina Arkhipova, James G Christensen, Matthew A Marx

RSC Med Chem· December 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and evaluation of achiral, non-atropisomeric 4-(aminomethyl)phthalazin-1(2H)-one derivatives as novel PRMT5/MTA inhibitors.
Christopher R Smith, Ruth Aranda, James G Christensen, Lars D Engstrom, Robin J Gunn, Matthew A Marx

Bioorg Med Chem· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor efficacy of a potent and selective non-covalent KRAS inhibitor.
Jill Hallin, Vickie Bowcut, Andrew Calinisan, David M Briere, Lauren Hargis, Matthew A Marx

Nat Med· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atropisomeric Racemization Kinetics of MRTX1719 Using Chiral Solvating Agent-Assisted F NMR Spectroscopy.
Svitlana Kulyk, Susan M De Paul, Matthew A Marx, Torren M Peakman, Christopher R Smith

ACS Omega· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and Discovery of MRTX0902, a Potent, Selective, Brain-Penetrant, and Orally Bioavailable Inhibitor of the SOS1:KRAS Protein-Protein Interaction.
John M Ketcham, Jacob Haling, Shilpi Khare, Vickie Bowcut, David M Briere, Matthew A Marx

J Med Chem· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of MRTX1133, a Noncovalent, Potent, and Selective KRAS Inhibitor.
Xiaolun Wang, Shelley Allen, James F Blake, Vickie Bowcut, David M Briere, Matthew A Marx

J Med Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Fragment-Based Discovery of MRTX1719, a Synthetic Lethal Inhibitor of the PRMT5•MTA Complex for the Treatment of -Deleted Cancers.
Christopher R Smith, Ruth Aranda, Thomas P Bobinski, David M Briere, Aaron C Burns, Matthew A Marx

J Med Chem· February 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Identification of the Clinical Development Candidate , a Covalent KRAS Inhibitor for the Treatment of Cancer.
Jay B Fell, John P Fischer, Brian R Baer, James F Blake, Karyn Bouhana, Matthew A Marx

J Med Chem· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The KRAS Inhibitor MRTX849 Provides Insight toward Therapeutic Susceptibility of KRAS-Mutant Cancers in Mouse Models and Patients.
Jill Hallin, Lars D Engstrom, Lauren Hargis, Andrew Calinisan, Ruth Aranda, Matthew A Marx

Cancer Discov· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Tetrahydropyridopyrimidines as Irreversible Covalent Inhibitors of KRAS-G12C with In Vivo Activity.
Jay B Fell, John P Fischer, Brian R Baer, Joshua Ballard, James F Blake, Matthew A Marx

ACS Med Chem Lett· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery and synthesis of novel 4-aminopyrrolopyrimidine Tie-2 kinase inhibitors for the treatment of solid tumors.
Joel T Arcari, Jean S Beebe, Martin A Berliner, Vincent Bernardo, Merin Boehm, Matthew A Marx

Bioorg Med Chem Lett· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of the Highly Potent PI3K/mTOR Dual Inhibitor PF-04979064 through Structure-Based Drug Design.
Hengmiao Cheng, Chunze Li, Simon Bailey, Sangita M Baxi, Lance Goulet, Matthew A Marx

ACS Med Chem Lett· January 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of novel, potent, and selective inhibitors of 3-phosphoinositide-dependent kinase (PDK1).
Sean T Murphy, Gordon Alton, Simon Bailey, Sangita M Baxi, Benjamin J Burke, Matthew A Marx

J Med Chem· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly Selective and Potent Thiophenes as PI3K Inhibitors with Oral Antitumor Activity.
Kevin K-C Liu, JinJiang Zhu, Graham L Smith, Min-Jean Yin, Simon Bailey, Matthew A Marx

ACS Med Chem Lett· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
4
4-methylpteridinones as orally active and selective PI3K/mTOR dual inhibitors.
Kevin K-C Liu, Shubha Bagrodia, Simon Bailey, Hengmiao Cheng, Hui Chen, Matthew A Marx

Bioorg Med Chem Lett· October 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
2-Morpholino-4-oxo-4,5-dihydro-thio-phene-3-carbonitrile.
Jinjiang Zhu, Kevin K Liu, Matthew A Marx, Arnold L Rheingold, Alex Yanovsky

Acta Crystallogr Sect E Struct Rep Online· October 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Design and SAR of thienopyrimidine and thienopyridine inhibitors of VEGFR-2 kinase activity.
Michael J Munchhof, Jean S Beebe, Jeffery M Casavant, Beth A Cooper, Jonathan L Doty, Matthew A Marx

Bioorg Med Chem Lett· January 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis